HASTINGS PAUL J
Insider CIK 1309702 · OMED President & CEO, Director · PRTO Director · PCRX Director · RLYP Director · NKTX See Remarks, Director · ENGN Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| NKTX Nkarta, Inc. | S Sale | 2026-06-18 | 2026-06-22 | 1,776 | $2.71 | $4.8K | 390,247 | SEC↗ |
| ENGN enGene Therapeutics Inc. | A Award deriv | 2026-06-16 | 2026-06-17 | 31,000 | — | $0 | 31,000 | SEC↗ |
| NKTX Nkarta, Inc. | S Sale | 2026-01-15 | 2026-01-20 | 26,046 | $2.07 | $53.9K | 390,023 | SEC↗ |
| NKTX Nkarta, Inc. | A Award deriv | 2026-01-06 | 2026-01-08 | 562,000 | — | $0 | 562,000 | SEC↗ |
| NKTX Nkarta, Inc. | A Award | 2026-01-06 | 2026-01-08 | 94,000 | — | $0 | 416,069 | SEC↗ |
| NKTX Nkarta, Inc. | S Sale | 2025-06-18 | 2025-06-20 | 1,790 | $1.79 | $3.2K | 320,069 | SEC↗ |
| ENGN enGene Holdings Inc. | A Award deriv | 2025-06-16 | 2025-06-16 | 22,500 | — | $0 | 22,500 | SEC↗ |
| NKTX Nkarta, Inc. | A Award deriv | 2025-06-05 | 2025-06-09 | 377,000 | — | $0 | 377,000 | SEC↗ |
| NKTX Nkarta, Inc. | S Sale | 2025-01-15 | 2025-01-17 | 17,378 | $2.20 | $38.2K | 319,859 | SEC↗ |
| NKTX Nkarta, Inc. | A Award deriv | 2025-01-03 | 2025-01-07 | 565,500 | — | $0 | 565,500 | SEC↗ |
| NKTX Nkarta, Inc. | A Award | 2025-01-03 | 2025-01-07 | 94,500 | — | $0 | 337,237 | SEC↗ |
| NKTX Nkarta, Inc. | S Sale | 2024-06-18 | 2024-06-20 | 1,770 | $5.60 | $9.9K | 240,737 | SEC↗ |
| ENGN enGene Holdings Inc. | A Award deriv | 2024-06-15 | 2024-06-18 | 40,000 | — | $0 | 40,000 | SEC↗ |
| PCRX Pacira BioSciences, Inc. | S Sale | 2024-06-13 | 2024-06-13 | 880 | $28.38 | $25.0K | 12,724 | SEC↗ |
| PCRX Pacira BioSciences, Inc. | A Award deriv | 2024-06-12 | 2024-06-13 | 12,179 | — | $0 | 12,179 | SEC↗ |
| PCRX Pacira BioSciences, Inc. | A Award | 2024-06-12 | 2024-06-13 | 5,230 | — | $0 | 13,604 | SEC↗ |
| NKTX Nkarta, Inc. | D To issuer | 2024-03-04 | 2024-03-05 | 137,642 | $13.33 | $1.83M | 240,507 | SEC↗ |
| NKTX Nkarta, Inc. | D To issuer | 2024-03-01 | 2024-03-05 | 12,358 | $13.00 | $160.7K | 378,149 | SEC↗ |
| NKTX Nkarta, Inc. | S Sale | 2024-01-16 | 2024-01-18 | 9,697 | $8.74 | $84.8K | 390,507 | SEC↗ |
| NKTX Nkarta, Inc. | A Award deriv | 2024-01-04 | 2024-01-08 | 509,500 | — | $0 | 509,500 | SEC↗ |
| NKTX Nkarta, Inc. | A Award | 2024-01-04 | 2024-01-08 | 85,000 | — | $0 | 400,204 | SEC↗ |
| NKTX Nkarta, Inc. | S Sale | 2023-06-20 | 2023-06-22 | 1,704 | $4.85 | $8.3K | 313,402 | SEC↗ |
| PCRX Pacira BioSciences, Inc. | A Award deriv | 2023-06-14 | 2023-06-16 | 12,925 | — | $0 | 12,925 | SEC↗ |
| PCRX Pacira BioSciences, Inc. | A Award | 2023-06-14 | 2023-06-16 | 1,775 | — | $0 | 8,374 | SEC↗ |
| PCRX Pacira BioSciences, Inc. | S Sale | 2023-06-05 | 2023-06-07 | 580 | $38.34 | $22.2K | 6,599 | SEC↗ |
| PCRX Pacira BioSciences, Inc. | M Exercise deriv | 2023-05-15 | 2023-05-17 | 7,000 | — | $0 | 0 | SEC↗ |
| PCRX Pacira BioSciences, Inc. | S Sale | 2023-05-15 | 2023-05-17 | 7,000 | $41.85 | $292.9K | 7,179 | SEC↗ |
| PCRX Pacira BioSciences, Inc. | M Exercise | 2023-05-15 | 2023-05-17 | 7,000 | $29.90 | $209.3K | 14,179 | SEC↗ |
| NKTX Nkarta, Inc. | S Sale | 2023-01-17 | 2023-01-18 | 3,691 | $5.49 | $20.3K | 313,106 | SEC↗ |
| NKTX Nkarta, Inc. | A Award deriv | 2023-01-13 | 2023-01-18 | 386,500 | — | $0 | 386,500 | SEC↗ |
| NKTX Nkarta, Inc. | A Award | 2023-01-13 | 2023-01-18 | 64,500 | — | $0 | 316,797 | SEC↗ |
| NKTX Nkarta, Inc. | S Sale | 2022-09-29 | 2022-09-30 | 498 | $13.00 | $6.5K | 250,461 | SEC↗ |
| NKTX Nkarta, Inc. | S Sale | 2022-09-28 | 2022-09-30 | 23,376 | $13.03 | $304.6K | 250,959 | SEC↗ |
| NKTX Nkarta, Inc. | S Sale | 2022-09-21 | 2022-09-22 | 6,126 | $13.01 | $79.7K | 274,335 | SEC↗ |
| PCRX Pacira BioSciences, Inc. | S Sale | 2022-07-11 | 2022-07-13 | 533 | $56.95 | $30.4K | 7,179 | SEC↗ |
| NKTX Nkarta, Inc. | A Award deriv | 2022-06-17 | 2022-06-21 | 120,000 | — | $0 | 120,000 | SEC↗ |
| NKTX Nkarta, Inc. | A Award | 2022-06-17 | 2022-06-21 | 19,500 | — | $0 | 280,461 | SEC↗ |
| PCRX Pacira BioSciences, Inc. | A Award deriv | 2022-06-08 | 2022-06-08 | 8,225 | — | $0 | 8,225 | SEC↗ |
| PCRX Pacira BioSciences, Inc. | A Award | 2022-06-08 | 2022-06-08 | 1,160 | — | $0 | 7,712 | SEC↗ |
| NKTX Nkarta, Inc. | A Award deriv | 2022-01-14 | 2022-01-19 | 251,100 | — | $0 | 251,100 | SEC↗ |
| NKTX Nkarta, Inc. | A Award | 2022-01-14 | 2022-01-19 | 41,900 | — | $0 | 260,961 | SEC↗ |
| NKTX Nkarta, Inc. | S Sale | 2021-09-29 | 2021-10-01 | 223 | $26.53 | $5.9K | 219,061 | SEC↗ |
| NKTX Nkarta, Inc. | S Sale | 2021-09-29 | 2021-10-01 | 8,277 | $27.20 | $225.1K | 219,284 | SEC↗ |
| NKTX Nkarta, Inc. | S Sale | 2021-06-21 | 2021-06-23 | 3,807 | $26.89 | $102.4K | 227,561 | SEC↗ |
| NKTX Nkarta, Inc. | S Sale | 2021-06-21 | 2021-06-23 | 4,693 | $26.39 | $123.8K | 231,368 | SEC↗ |
| PCRX Pacira BioSciences, Inc. | A Award deriv | 2021-06-09 | 2021-06-11 | 7,626 | — | $0 | 7,626 | SEC↗ |
| PCRX Pacira BioSciences, Inc. | A Award | 2021-06-09 | 2021-06-11 | 1,066 | — | $0 | 6,552 | SEC↗ |
| PCRX Pacira BioSciences, Inc. | S Sale | 2021-06-04 | 2021-06-08 | 630 | $62.19 | $39.2K | 5,486 | SEC↗ |
| NKTX Nkarta, Inc. | S Sale | 2021-03-30 | 2021-04-01 | 3,130 | $32.21 | $100.8K | 236,061 | SEC↗ |
| NKTX Nkarta, Inc. | S Sale | 2021-03-30 | 2021-04-01 | 11,461 | $30.23 | $346.5K | 241,600 | SEC↗ |
| NKTX Nkarta, Inc. | S Sale | 2021-03-30 | 2021-04-01 | 2,409 | $31.24 | $75.3K | 239,191 | SEC↗ |
| PCRX Pacira BioSciences, Inc. | M Exercise deriv | 2021-03-05 | 2021-03-09 | 3,000 | — | $0 | 0 | SEC↗ |
| PCRX Pacira BioSciences, Inc. | S Sale | 2021-03-05 | 2021-03-09 | 3,000 | $65.88 | $197.6K | 6,116 | SEC↗ |
| PCRX Pacira BioSciences, Inc. | M Exercise | 2021-03-05 | 2021-03-09 | 3,000 | $13.98 | $41.9K | 9,116 | SEC↗ |
| NKTX Nkarta, Inc. | A Award deriv | 2021-01-08 | 2021-01-12 | 157,500 | — | $0 | 157,500 | SEC↗ |
| NKTX Nkarta, Inc. | A Award deriv | 2020-07-09 | 2020-07-13 | 202,400 | — | $0 | 202,400 | SEC↗ |
| PCRX Pacira BioSciences, Inc. | A Award deriv | 2020-06-09 | 2020-06-11 | 8,027 | — | $0 | 8,027 | SEC↗ |
| PCRX Pacira BioSciences, Inc. | A Award | 2020-06-09 | 2020-06-11 | 1,260 | — | $0 | 6,116 | SEC↗ |
| PCRX Pacira BioSciences, Inc. | S Sale | 2020-06-04 | 2020-06-08 | 2,025 | $47.46 | $96.1K | 4,856 | SEC↗ |
| PCRX Pacira BioSciences, Inc. | A Award deriv | 2019-06-05 | 2019-06-06 | 8,437 | — | $0 | 8,437 | SEC↗ |
| PCRX Pacira BioSciences, Inc. | A Award | 2019-06-05 | 2019-06-06 | 4,134 | — | $0 | 6,881 | SEC↗ |
| PCRX Pacira BioSciences, Inc. | S Sale | 2019-06-04 | 2019-06-06 | 782 | $42.66 | $33.4K | 2,747 | SEC↗ |
| PCRX Pacira Pharmaceuticals, In | A Award deriv | 2018-06-13 | 2018-06-15 | 4,693 | — | $0 | 4,693 | SEC↗ |
| PCRX Pacira Pharmaceuticals, In | A Award | 2018-06-13 | 2018-06-15 | 782 | — | $0 | 3,529 | SEC↗ |
| PRTO PROTEON THERAPEUTICS INC | A Award deriv | 2018-06-08 | 2018-06-11 | 12,700 | — | $0 | 12,700 | SEC↗ |
| PCRX Pacira Pharmaceuticals, In | S Sale | 2018-06-04 | 2018-06-06 | 771 | $33.90 | $26.1K | 2,747 | SEC↗ |
| OMED OncoMed Pharmaceuticals In | S Sale | 2017-10-10 | 2017-10-12 | 1,346 | $4.24 | $5.7K | 76,188 | SEC↗ |
| OMED OncoMed Pharmaceuticals In | S Sale | 2017-10-10 | 2017-10-12 | 52 | $4.26 | $222 | 77,534 | SEC↗ |
| PCRX Pacira Pharmaceuticals, In | S Sale | 2017-08-22 | 2017-08-24 | 1,044 | $36.15 | $37.7K | 3,518 | SEC↗ |
| PRTO PROTEON THERAPEUTICS INC | A Award deriv | 2017-06-20 | 2017-06-21 | 6,666 | — | $0 | 6,666 | SEC↗ |
| PCRX Pacira Pharmaceuticals, In | A Award deriv | 2017-06-14 | 2017-06-16 | 2,714 | — | $0 | 2,714 | SEC↗ |
| PCRX Pacira Pharmaceuticals, In | A Award | 2017-06-14 | 2017-06-16 | 1,357 | — | $0 | 4,562 | SEC↗ |
| OMED OncoMed Pharmaceuticals In | A Award deriv | 2017-04-24 | 2017-04-25 | 135,000 | — | $0 | 135,000 | SEC↗ |
| OMED OncoMed Pharmaceuticals In | A Award | 2017-04-24 | 2017-04-25 | 45,000 | — | $0 | 77,586 | SEC↗ |
| OMED OncoMed Pharmaceuticals In | S Sale | 2017-04-04 | 2017-04-05 | 48 | $8.87 | $426 | 39,011 | SEC↗ |
| OMED OncoMed Pharmaceuticals In | S Sale | 2017-04-04 | 2017-04-05 | 6,425 | $9.06 | $58.2K | 32,586 | SEC↗ |
| OMED OncoMed Pharmaceuticals In | M Exercise deriv | 2017-01-06 | 2017-01-09 | 21,369 | — | $0 | 0 | SEC↗ |
| OMED OncoMed Pharmaceuticals In | M Exercise | 2017-01-06 | 2017-01-09 | 21,369 | $1.43 | $30.6K | 58,692 | SEC↗ |
| OMED OncoMed Pharmaceuticals In | S Sale | 2017-01-06 | 2017-01-09 | 21,369 | $8.52 | $182.1K | 37,323 | SEC↗ |
| OMED OncoMed Pharmaceuticals In | M Exercise deriv | 2017-01-05 | 2017-01-09 | 21,369 | — | $0 | 21,369 | SEC↗ |
| OMED OncoMed Pharmaceuticals In | M Exercise | 2017-01-05 | 2017-01-09 | 21,369 | $1.43 | $30.6K | 58,692 | SEC↗ |
| OMED OncoMed Pharmaceuticals In | S Sale | 2017-01-05 | 2017-01-09 | 21,369 | $8.17 | $174.6K | 37,323 | SEC↗ |
| OMED OncoMed Pharmaceuticals In | A Award deriv | 2017-01-03 | 2017-01-05 | 176,000 | — | $0 | 176,000 | SEC↗ |
| PRTO PROTEON THERAPEUTICS INC | A Award deriv | 2016-10-18 | 2016-10-20 | 13,333 | — | $0 | 13,333 | SEC↗ |
| OMED OncoMed Pharmaceuticals In | A Award | 2016-10-09 | 2016-10-11 | 14,000 | — | $0 | 37,323 | SEC↗ |
| RLYP Relypsa Inc | D To issuer deriv | 2016-09-01 | 2016-09-02 | 15,953 | — | $0 | 0 | SEC↗ |
| RLYP Relypsa Inc | D To issuer deriv | 2016-09-01 | 2016-09-02 | 4,500 | — | $0 | 0 | SEC↗ |
| RLYP Relypsa Inc | D To issuer deriv | 2016-09-01 | 2016-09-02 | 4,500 | — | $0 | 0 | SEC↗ |
| RLYP Relypsa Inc | D To issuer deriv | 2016-09-01 | 2016-09-02 | 3,828 | — | $0 | 0 | SEC↗ |
| RLYP Relypsa Inc | D To issuer deriv | 2016-09-01 | 2016-09-02 | 21,802 | — | $0 | 0 | SEC↗ |
| RLYP Relypsa Inc | D To issuer | 2016-09-01 | 2016-09-02 | 2,250 | $32.00 | $72.0K | 0 | SEC↗ |
| RLYP Relypsa Inc | U Tender | 2016-09-01 | 2016-09-02 | 2,495 | $32.00 | $79.8K | 2,250 | SEC↗ |
| RLYP Relypsa Inc | A Award deriv | 2016-06-21 | 2016-06-23 | 4,500 | — | $0 | 4,500 | SEC↗ |
| RLYP Relypsa Inc | A Award | 2016-06-21 | 2016-06-23 | 2,250 | — | $0 | 4,745 | SEC↗ |
| PCRX Pacira Pharmaceuticals, In | A Award deriv | 2016-06-15 | 2016-06-17 | 2,975 | — | $0 | 2,975 | SEC↗ |
| PCRX Pacira Pharmaceuticals, In | A Award | 2016-06-15 | 2016-06-17 | 1,488 | — | $0 | 3,205 | SEC↗ |
| RLYP Relypsa Inc | S Sale | 2016-06-07 | 2016-06-08 | 1,013 | $19.32 | $19.6K | 2,495 | SEC↗ |
| PCRX Pacira Pharmaceuticals, In | S Sale | 2016-06-06 | 2016-06-08 | 1,136 | $46.95 | $53.3K | 1,717 | SEC↗ |
| PCRX Pacira Pharmaceuticals, In | M Exercise deriv | 2016-02-17 | 2016-02-22 | 2,000 | — | $0 | 3,000 | SEC↗ |
| PCRX Pacira Pharmaceuticals, In | M Exercise deriv | 2016-02-17 | 2016-02-22 | 1,000 | — | $0 | 0 | SEC↗ |
| PCRX Pacira Pharmaceuticals, In | M Exercise | 2016-02-17 | 2016-02-22 | 1,000 | $10.81 | $10.8K | 5,853 | SEC↗ |
| PCRX Pacira Pharmaceuticals, In | S Sale | 2016-02-17 | 2016-02-22 | 3,000 | $60.00 | $180.0K | 2,853 | SEC↗ |
| PCRX Pacira Pharmaceuticals, In | M Exercise | 2016-02-17 | 2016-02-22 | 2,000 | $13.98 | $28.0K | 4,853 | SEC↗ |
| OMED OncoMed Pharmaceuticals In | S Sale | 2016-01-06 | 2016-01-08 | 77 | $21.54 | $1.7K | 22,025 | SEC↗ |
| OMED OncoMed Pharmaceuticals In | S Sale | 2016-01-06 | 2016-01-08 | 2,335 | $22.30 | $52.1K | 22,102 | SEC↗ |
| OMED OncoMed Pharmaceuticals In | A Award deriv | 2015-12-28 | 2016-03-25 | 170,000 | — | $0 | 170,000 | SEC↗ |
| OMED OncoMed Pharmaceuticals In | A Award deriv | 2015-12-27 | 2015-12-29 | 170,000 | — | $0 | 170,000 | SEC↗ |
| PCRX Pacira Pharmaceuticals, In | M Exercise deriv | 2015-11-20 | 2015-11-24 | 3,000 | — | $0 | 1,000 | SEC↗ |
| PCRX Pacira Pharmaceuticals, In | S Sale | 2015-11-20 | 2015-11-24 | 3,000 | $60.00 | $180.0K | 2,853 | SEC↗ |
| PCRX Pacira Pharmaceuticals, In | M Exercise | 2015-11-20 | 2015-11-24 | 3,000 | $10.81 | $32.4K | 5,853 | SEC↗ |
| PCRX Pacira Pharmaceuticals, In | M Exercise deriv | 2015-08-17 | 2015-08-19 | 3,000 | — | $0 | 4,000 | SEC↗ |
| PCRX Pacira Pharmaceuticals, In | S Sale | 2015-08-17 | 2015-08-19 | 3,000 | $60.02 | $180.1K | 2,853 | SEC↗ |
| PCRX Pacira Pharmaceuticals, In | M Exercise | 2015-08-17 | 2015-08-19 | 3,000 | $10.81 | $32.4K | 5,853 | SEC↗ |
| RLYP Relypsa Inc | S Sale | 2015-06-11 | 2015-06-15 | 1,454 | $34.63 | $50.4K | 3,508 | SEC↗ |
| RLYP Relypsa Inc | A Award deriv | 2015-06-04 | 2015-06-08 | 4,500 | — | $0 | 4,500 | SEC↗ |
| RLYP Relypsa Inc | A Award | 2015-06-04 | 2015-06-08 | 2,250 | — | $0 | 4,962 | SEC↗ |
| PCRX Pacira Pharmaceuticals, In | A Award deriv | 2015-06-03 | 2015-06-05 | 4,000 | — | $0 | 4,000 | SEC↗ |
| PCRX Pacira Pharmaceuticals, In | A Award | 2015-06-03 | 2015-06-05 | 2,000 | — | $0 | 2,853 | SEC↗ |
| PCRX Pacira Pharmaceuticals, In | M Exercise deriv | 2015-04-10 | 2015-04-14 | 2,500 | — | $0 | 5,000 | SEC↗ |
| PCRX Pacira Pharmaceuticals, In | S Sale | 2015-04-10 | 2015-04-14 | 2,500 | $88.00 | $220.0K | 853 | SEC↗ |
| PCRX Pacira Pharmaceuticals, In | M Exercise | 2015-04-10 | 2015-04-14 | 2,500 | $13.98 | $35.0K | 3,353 | SEC↗ |
| PCRX Pacira Pharmaceuticals, In | M Exercise deriv | 2015-01-12 | 2015-01-14 | 2,500 | — | $0 | 7,500 | SEC↗ |
| PCRX Pacira Pharmaceuticals, In | M Exercise | 2015-01-12 | 2015-01-14 | 2,500 | $13.98 | $35.0K | 3,353 | SEC↗ |
| PCRX Pacira Pharmaceuticals, In | S Sale | 2015-01-12 | 2015-01-14 | 2,500 | $94.06 | $235.2K | 853 | SEC↗ |
| OMED OncoMed Pharmaceuticals In | A Award deriv | 2014-12-18 | 2014-12-22 | 140,000 | — | $0 | 140,000 | SEC↗ |
| OMED OncoMed Pharmaceuticals In | M Exercise deriv | 2014-10-29 | 2014-10-30 | 8,385 | — | $0 | 42,738 | SEC↗ |
| OMED OncoMed Pharmaceuticals In | M Exercise | 2014-10-29 | 2014-10-30 | 8,385 | $1.43 | $12.0K | 31,616 | SEC↗ |
| OMED OncoMed Pharmaceuticals In | S Sale | 2014-10-29 | 2014-10-30 | 8,385 | $21.90 | $183.6K | 23,231 | SEC↗ |
| OMED OncoMed Pharmaceuticals In | M Exercise deriv | 2014-10-28 | 2014-10-30 | 8,384 | — | $0 | 51,123 | SEC↗ |
| OMED OncoMed Pharmaceuticals In | M Exercise | 2014-10-28 | 2014-10-30 | 8,384 | $1.43 | $12.0K | 31,615 | SEC↗ |
| OMED OncoMed Pharmaceuticals In | S Sale | 2014-10-28 | 2014-10-30 | 8,384 | $22.08 | $185.1K | 23,231 | SEC↗ |
| PCRX Pacira Pharmaceuticals, In | M Exercise deriv | 2014-10-10 | 2014-10-14 | 2,500 | — | $0 | 10,000 | SEC↗ |
| PCRX Pacira Pharmaceuticals, In | S Sale | 2014-10-10 | 2014-10-14 | 2,500 | $94.87 | $237.2K | 853 | SEC↗ |
| PCRX Pacira Pharmaceuticals, In | M Exercise | 2014-10-10 | 2014-10-14 | 2,500 | $13.98 | $35.0K | 3,353 | SEC↗ |
| OMED OncoMed Pharmaceuticals In | M Exercise deriv | 2014-07-29 | 2014-07-30 | 8,385 | — | $0 | 59,507 | SEC↗ |
| OMED OncoMed Pharmaceuticals In | M Exercise | 2014-07-29 | 2014-07-30 | 8,385 | $1.43 | $12.0K | 30,885 | SEC↗ |
| OMED OncoMed Pharmaceuticals In | S Sale | 2014-07-29 | 2014-07-30 | 8,385 | $22.28 | $186.8K | 22,500 | SEC↗ |
| OMED OncoMed Pharmaceuticals In | M Exercise deriv | 2014-07-28 | 2014-07-30 | 8,385 | — | $0 | 67,892 | SEC↗ |
| OMED OncoMed Pharmaceuticals In | S Sale | 2014-07-28 | 2014-07-30 | 8,285 | $21.93 | $181.7K | 22,600 | SEC↗ |
| OMED OncoMed Pharmaceuticals In | S Sale | 2014-07-28 | 2014-07-30 | 100 | $22.70 | $2.3K | 22,500 | SEC↗ |
| OMED OncoMed Pharmaceuticals In | M Exercise | 2014-07-28 | 2014-07-30 | 8,385 | $1.43 | $12.0K | 30,885 | SEC↗ |
| PCRX Pacira Pharmaceuticals, In | M Exercise deriv | 2014-07-10 | 2014-07-11 | 2,500 | — | $0 | 12,500 | SEC↗ |
| PCRX Pacira Pharmaceuticals, In | M Exercise | 2014-07-10 | 2014-07-11 | 2,500 | $13.98 | $35.0K | 3,353 | SEC↗ |
| PCRX Pacira Pharmaceuticals, In | S Sale | 2014-07-10 | 2014-07-11 | 600 | $82.46 | $49.5K | 2,753 | SEC↗ |
| PCRX Pacira Pharmaceuticals, In | S Sale | 2014-07-10 | 2014-07-11 | 502 | $85.03 | $42.7K | 1,551 | SEC↗ |
| PCRX Pacira Pharmaceuticals, In | S Sale | 2014-07-10 | 2014-07-11 | 698 | $85.96 | $60.0K | 853 | SEC↗ |
| PCRX Pacira Pharmaceuticals, In | S Sale | 2014-07-10 | 2014-07-11 | 700 | $84.08 | $58.9K | 2,053 | SEC↗ |
| RLYP Relypsa Inc | A Award deriv | 2014-06-19 | 2014-06-23 | 3,828 | — | $0 | 3,828 | SEC↗ |
| RLYP Relypsa Inc | A Award | 2014-06-19 | 2014-06-23 | 2,712 | — | $0 | 2,712 | SEC↗ |
| PCRX Pacira Pharmaceuticals, In | A Award deriv | 2014-06-03 | 2014-06-05 | 8,000 | — | $0 | 8,000 | SEC↗ |
| OMED OncoMed Pharmaceuticals In | A Award | 2014-03-25 | 2014-03-27 | 22,500 | — | $0 | 23,575 | SEC↗ |
| OMED OncoMed Pharmaceuticals In | C Conversion deriv | 2013-07-23 | 2013-07-23 | 12,531 | — | $0 | 0 | SEC↗ |
| OMED OncoMed Pharmaceuticals In | C Conversion deriv | 2013-07-23 | 2013-07-23 | 10,320 | — | $0 | 0 | SEC↗ |
| OMED OncoMed Pharmaceuticals In | C Conversion deriv | 2013-07-23 | 2013-07-23 | 17,543 | — | $0 | 0 | SEC↗ |
| OMED OncoMed Pharmaceuticals In | C Conversion | 2013-07-23 | 2013-07-23 | 10,320 | — | $0 | 323,765 | SEC↗ |
| OMED OncoMed Pharmaceuticals In | C Conversion | 2013-07-23 | 2013-07-23 | 12,531 | — | $0 | 313,445 | SEC↗ |
| OMED OncoMed Pharmaceuticals In | C Conversion | 2013-07-23 | 2013-07-23 | 17,543 | — | $0 | 300,914 | SEC↗ |
| OMED OncoMed Pharmaceuticals In | A Award deriv | 2013-07-17 | 2013-07-19 | 160,000 | — | $0 | 160,000 | SEC↗ |
| PCRX Pacira Pharmaceuticals, In | A Award deriv | 2013-06-12 | 2013-06-14 | 7,000 | — | $0 | 7,000 | SEC↗ |
| PCRX Pacira Pharmaceuticals, In | P Buy | 2013-05-15 | 2013-05-17 | 853 | $29.30 | $25.0K | 853 | SEC↗ |
| PCRX Pacira Pharmaceuticals, In | A Award deriv | 2012-06-05 | 2012-06-07 | 7,000 | — | $0 | 7,000 | SEC↗ |